Alx Oncology Holdings (ALXO) Assets (2019 - 2026)
Alx Oncology Holdings (ALXO) posted Assets of $178.3 million for Q1 2026, up 202.02% sequentially from $59.0 million in Q4 2025, and up 47.5% YoY from $120.9 million in Q1 2025.
Analysis
Alx Oncology Holdings (ALXO) Assets (2019 - 2026) Analysis & Trends
Alx Oncology Holdings has reported Assets for 8 years, with the latest figure at $178.3 million in Q1 2026.
- Quarterly Assets rose 47.5% year-over-year to $178.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.3 million (up 47.5% YoY) and the FY2025 annual result came in at $59.0 million, down 60.04% from the prior year.
- Assets rose to $178.3 million in Q1 2026 per ALXO's latest filing, from $59.0 million in the prior quarter.
- Over five years, Assets peaked at $363.7 million in Q1 2022 and troughed at $59.0 million in Q4 2025.
- A 5-year average of $212.8 million and a median of $214.6 million in 2024 frame the typical range for Assets.
- The sharpest annual moves came in 2025 and 2026: Assets tumbled 60.04% in 2025, then jumped 47.5% in 2026.
- Over 5 years, Assets stood at $306.5 million in 2022, then slipped by 20.86% to $242.6 million in 2023, then plunged by 39.08% to $147.8 million in 2024, then sank by 60.04% to $59.0 million in 2025, then jumped by 202.02% to $178.3 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $178.3 million, $59.0 million, and $82.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Alx Oncology Holdings | 273.99 Mn | 273.99 Mn | - | 160.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 160.82 Mn |
| Mar 31, 2026 | 178.33 Mn |
| Dec 31, 2025 | 59.05 Mn |
| Sep 30, 2025 | 82.72 Mn |
| Jun 30, 2025 | 95.32 Mn |
| Mar 31, 2025 | 120.90 Mn |
| Dec 31, 2024 | 147.78 Mn |
| Sep 30, 2024 | 185.72 Mn |
| Jun 30, 2024 | 214.62 Mn |
| Mar 31, 2024 | 212.65 Mn |
| Dec 31, 2023 | 242.55 Mn |
| Sep 30, 2023 | 220.11 Mn |
| Jun 30, 2023 | 245.93 Mn |
| Mar 31, 2023 | 278.14 Mn |
| Dec 31, 2022 | 306.49 Mn |
| Sep 30, 2022 | 317.69 Mn |
| Jun 30, 2022 | 346.02 Mn |
| Mar 31, 2022 | 363.68 Mn |
| Dec 31, 2021 | 380.18 Mn |
| Sep 30, 2021 | 399.73 Mn |